Description
This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 5
Primary Industries
- Drugs
- Biotechnology
- Diagnostic
- Cancer
- Disease
- Drug Discovery
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 28619
License Grant
Licensor of England hereby grants to the Licensee of England a non-transferable, exclusive license in the Field under the Patents, with the right to sub-license to develop, manufacture, have manufactured, use and sell Licensed Products or to supply a Service but in each case only in the Field in the Territory.
License Property
Licensor has developed and owns a technology relating to chromatin, necleosome and histone structure and the determination of histone modifications particularly as the basis of methods for the diagnosis, prognosis and monitoring of cancer and other diseases (the Technology).
Chromatin is the combination of DNA and proteins that make up the contents of the nucleus of a cell. The primary functions of chromatin are 1) to package DNA into a smaller volume to fit in the cell, 2) to strengthen the DNA to allow mitosis, 3) to prevent DNA damage, and 4) to control gene expression and DNA replication.
A nucleosome is the basic unit of DNA packaging in eukaryotes, consisting of a segment of DNA wound in sequence around eight[1] histone protein cores.
In biology, histones are highly alkaline proteins found in eukaryotic cell nuclei that package and order the DNA into structural units called nucleosomes.
The Patents
Reference
Country Title
W02005/019826 AI Worldwide Detection of Histone Modifications in Cell-Free Nucleosomes
Priority Date Application No. Publication No.
Case Status
18-Aug-03 PCT/GB2004/003564
W02005/019826 AI National phase
Field of Use
Field The diagnosis, prevention and treatment of disease and pharmacogenomic applications and the provision of technology, products or services including the detection or identification of actual or potential gene expression or the characterization or identification of cell types or differentiation states.
IPSCIO Record ID: 4252
License Grant
College in England hereby grants to the Licensee of England an exclusive license in the Field under the Patents, with the right to sub-license to develop, manufacture, have manufactured, use and sell Licensed Products or to supply a Service but only in the Field in the Territory.
License Property
The College had developed and owned technology relating to hypersensitive sites and the determination of chromatin structure, methods of modifying chromatin structure and a library of hypersensitive sites (the Technology).
Patent Application
GB 0116453.2
PCT/GB0203080
WO03/004702
Field of Use
Field The diagnosis, prevention and treatment of disease and pharmacogenomics applications and the provision of technology, products or services including the detection or identification of actual or potential gene expression or the characterization or identification of cell types or differentiation states.
IPSCIO Record ID: 27792
License Grant
The Singapore Licensor hereby grants to Licensee of Belgium a non-transferable, exclusive license in the Field under the Patents, with the right to sub-license, subject to clause 1.3 below, to develop, manufacture, have manufactured, use and sell Licensed Products or to supply a Service but in each case only in the Field in the Territory.
License Property
Licensed Products Any and all products that are manufactured, sold or otherwise supplied by the Licensee or its sub-licensee (including any Affiliate of the Licensee) and which are within any Valid Claim of the Patent No. PCT/GB2004/ 003564.
Field of Use
Field The diagnosis, prevention, treatment of disease and pharmacogenomic applications and the provision of technology, products or services including the detection or identification of actual or potential gene expression or the characterization or identification of cell types or differentiation states. It is intended to include therapeutic monitoring and the use of the IPR in therapeutic regime design and monitoring including the use of the IPR in therapeutic discovery and development both clinically and non-clinically. Material used may be Human tissues, physiological fluids and other human and animal derived material directly or indirectly obtained.
IPSCIO Record ID: 269
License Grant
The Singapore Licensor hereby grants to the Licensee of England a transferable, exclusive license in the Field under the Patents to manufacture, use and sell or otherwise supply Licensed Products in the Territory.
License Property
The Patents
Reference
Country
Title
.
WO2002GB03080
worldwide
Method for Determining Chromatin Structure
Priority Date 05/07/2001
Application No. PCT/GB02/03080
Publication No. WO202GB03080 20020704
Case Status Pending
Field of Use
Field The development and/or sale of Companion Diagnostic Material for use only and specifically with products that Licensee or its Affiliate has, is or will be developing from its currently owned or licensed therapeutic development technologies – namely;
· GeneICE as exemplified by patent nos. WO0102019, WO03033701 AND WO2004050885
· The peptide therapeutic compound licensed from Cancer Research Technology (CRT) as exemplified by Patent No. WO2008113770.
IPSCIO Record ID: 344585
License Grant
Licensor of England grants a worldwide non-exclusive license to use the System, the Cell Lines, the Materials, and the Intellectual Property to develop, manufacture, market and sell Product.
License Property
Licensor is the proprietor of a system for gene expression utilizing glutamine synthetase.
The patents are titled
Transformed Myeloma Cell-Line and a Process for the Expression of a Gene Coding for a Eukaryotic Polypeptide employing same;
Recombinant DNA Sequences, Vectors containing them and Method for the use thereof;
Recombinant DNA Product and Processes using it , and,
Recombinant DNA Methods, Vectors and Host Cells.
Product means DNA/histone directed antibody of human or chimeric origin, in combination with radio isotope or another component, of which antibody Licensee is the proprietor and which is obtained by the expression of any one gene or of any combination of genes by use of the Materials.
System means the glutamine synthetase gene expression system of which Licensor is the proprietor, as the same is described in the Intellectual Property.
Field of Use
The Licensee has been engaged in the development of drugs and related therapies for the treatment of people with cancer.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.
